ZE74-0282 (novel JAK2 V617F-targeting agent)

Current understanding

To be populated as evidence accumulates.

February 3 — Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor: cross-connection with prt12396-jak2v617f-mutant-selective-inhibitor: Both are mutant-selective JAK2V617F-targeting agents pursuing allele-burden modification, in contrast to pan-JAK inhibitors like ruxolitinib. (novelty: 4)
2026-04-14 — Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers: First-in-human, open-label, multi-center phase I dose-escalation trial launched to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ZE74-0282 in JAK2 V617F-positive blood cancers (trial-early). (novelty: 4)